Champions Oncology, Inc. CSBR
4.83 USD +0.02 (+0.42%)
At closeNov 3, 2026, 4:00 PM EST
4.83 0.00 0.00%
After hours · Nov 3, 4:00 PM ET
4.81 Day range 5.06
4.59 52-week range 8.31
- YTD
- -30.10%
- 1 year
- -28.97%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 8.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 1
- 1 month ago 1
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.01 | -0.01 – -0.01 | -0.16 | +93.8% | 12.93M | +7.6% | 1 |
| Next quarter | 0.06 | 0.06 – 0.06 | 0.01 | +500.0% | 15.67M | +11.9% | 1 |
| Current year | 0.21 | 0.21 – 0.21 | -0.46 | +145.6% | 56.15M | +11.9% | 1 |
| Next year | 0.24 | 0.24 – 0.24 | 0.21 | +14.3% | 61.83M | +10.1% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 12, 2024 | Craig-Hallum | Maintained | Buy | Buy |
| Sep 12, 2024 | Craig-Hallum | Upgrade | Hold | Buy |
| Mar 13, 2024 | Craig-Hallum | Downgrade | Buy | Hold |
| Sep 22, 2023 | Roth MKM | Maintained | Buy | Buy |
| Mar 15, 2021 | Roth Capital | Maintained | — | Buy |
| Nov 18, 2019 | Benchmark | Initiated | — | Speculative Buy |
| Sep 20, 2019 | Roth Capital | Initiated | — | Buy |
| Jul 24, 2019 | Janney Montgomery Scott | Downgrade | Buy | Neutral |
| Jul 17, 2018 | Craig-Hallum | Initiated | — | Buy |
| May 15, 2018 | Dawson James | Initiated | — | Buy |